ProbeChem®
*Expedite Your Scientific Research*

WWW.PROBECHEM.COM

# Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | SR4835 |
| **Cat. No.** | : | PC-73102 |
| **CAS No.** | : | 2387704-62-1 |
| **Molecular Formula** | : | $C_{21}H_{20}Cl_2N_{10}O$ |
| **Molecular Weight** | : | 499.36 |
| **Target** | : | Cyclin-dependent Kinase (CDK) |
| **Solubility** | : | 10 mM in DMSO |



## Biological Activity

SR-4835 (SR4835) is a potent, highly selective dual inhibitor of **CDK12** and **CDK13** with IC50 of 98 and 4.9 nM, respectively.
SR-4835 is highly selective toward CDK12 and CDK13 when tested in a panel of over 450 kinases at 10 uM, including CDK4, CDK6, CDK9, GSK3A, and GSK3B.
SR-4835 blocks Ser2 phosphorylation on the CTD of RNA Pol II (EC50=100 nM), has no affinity to BRD4 and does not inhibit PARP activity.
SR-4835 blocked clonogenic growth and survival of MDA-MB-231 cells (IC50=15.5 nM) with increased potency over THZ531.
SR-4835 suppressed the expression of DNA damage repair proteins accompanied with increased DNA damage and cell death in tumor cells.
SR-4835 synergizes with DNA-damaging chemotherapeutics cisplatin and provokes TNBC cell death by downregulating DNA repair proteins.
SR-4835/Cisplatin combination provokes tumor regression in an orthotopic TNBC PDX model.
SR-4835/Irinotecan combination provokes regression in BRCA1-deficient PDX model.

## References


Quereda V, et al. ***Cancer Cell.*** 2019 Nov 11;36(5):545-558.e7.

Hopkins JL, et al. ***Cancer Cell.*** 2019 Nov 11;36(5):461-463.

Li Y, et al. ***Cancer Lett.*** 2020 Dec 28;495:12-21.





E-mail: tech@probechem.com